Загрузка...
Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib
The clinical impact of HER2 inhibitors in the treatment of HER2-amplified breast cancers has been largely confined to chemotherapy combination regimens, since HER2 inhibitors appear to have very modest efficacies by themselves. This is due to the resilient nature of the functionally relevant HER2-HE...
Сохранить в:
| Опубликовано в: : | Oncotarget |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Impact Journals LLC
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4747394/ https://ncbi.nlm.nih.gov/pubmed/26516700 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|